| 0 (0%) | 09-27 12:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.2 |
1-year : | 2.57 |
| Resists | First : | 1.88 |
Second : | 2.2 |
| Pivot price | 1.25 |
|||
| Supports | First : | 1.31 |
Second : | 0.95 |
| MAs | MA(5) : | 1.54 |
MA(20) : | 1.21 |
| MA(100) : | 0.7 |
MA(250) : | 1.02 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 96.3 |
D(3) : | 87.1 |
| RSI | RSI(14): 80.2 |
|||
| 52-week | High : | 2.04 | Low : | 0.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ALXO ] has closed above the upper band by 9.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 281.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.89 - 1.9 | 1.9 - 1.91 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.86 - 1.87 | 1.87 - 1.88 |
Wed, 24 Sep 2025
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Mon, 22 Sep 2025
ALX Oncology (NASDAQ:ALXO) CEO Purchases $76,856.04 in Stock - MarketBeat
Fri, 19 Sep 2025
Friday 9/19 Insider Buying Report: AROC, ALXO - Nasdaq
Fri, 19 Sep 2025
$ALXO stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
Fri, 29 Aug 2025
Clinical-Stage Biotech ALX Oncology Announces Dual Conference Presentations in September 2025 - Stock Titan
Thu, 21 Aug 2025
Insider Buys Additional US$58k In ALX Oncology Holdings Stock - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 54 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 68.4 (%) |
| Shares Short | 1,820 (K) |
| Shares Short P.Month | 4,480 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.8 % |
| Return on Equity (ttm) | -104.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -105 (M) |
| Levered Free Cash Flow | -71 (M) |
| PE Ratio | -0.87 |
| PEG Ratio | 0 |
| Price to Book value | 1.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|